Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme
Article first published online: 18 FEB 2009
© 2009 The Authors Journal compilation © RCOG 2009 BJOG An International Journal of Obstetrics and Gynaecology
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 116, Issue 4, pages 594–598, March 2009
How to Cite
Tiller, H., Killie, M., Skogen, B., Øian, P. and Husebekk, A. (2009), Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG: An International Journal of Obstetrics & Gynaecology, 116: 594–598. doi: 10.1111/j.1471-0528.2008.02068.x
- Issue published online: 18 FEB 2009
- Article first published online: 18 FEB 2009
- Accepted 31 October 2008.
- Antenatal screening;
- anti-HPA1a antibodies;
- NAIT detection rate;
- neonatal alloimmune thrombocytopenia
The implementation of an antenatal screening programme for neonatal alloimmune thrombocytopenia (NAIT) is currently under debate. We evaluated the detection rate for NAIT in a nonscreened population of 661 200 births where NAIT was diagnosed on clinical indication. We did a cross-sectional comparison with a population of 100 448 human platelet antigen 1a (HPA1a)-screened pregnancies from three of the five health regions in Norway. In a nonscreening situation, 7.5 cases of NAIT were detected per year compared with 53 cases when screening was applied. The detection rate of NAIT in Norway was therefore 14% of the expected rate.